Citigroup Maintains Buy on Accendra Health, Lowers Price Target to $4.5

Benzinga Newsdesk www.benzinga.com Neutral 57.1%

Neg 0% Neu 57.1% Pos 0%

Citigroup analyst Daniel Grosslight maintains Accendra Health (NYSE:ACH) with a Buy and lowers the price target from $5 to $4.5.